-
公开(公告)号：US20200123160A1
公开(公告)日：2020-04-23
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07B59/00 , A61K51/04 , A61K31/55 , A61K31/5386 , A61K31/435 , A61K31/553 , A61K31/541 , A61K31/5377 , A61K31/5025 , A61K31/497 , A61K31/496 , A61K31/454 , A61K31/4439 , A61K31/433 , C07D513/04 , C07D519/00 , A61K45/06
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10428077B2
公开(公告)日：2019-10-01
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10047103B2
公开(公告)日：2018-08-14
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09688695B2
公开(公告)日：2017-06-27
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
5.发明授权Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors 有权同位素标记的三唑并吡啶11-β羟基类固醇脱氢酶I型抑制剂公开(公告)号：US09580422B2
公开(公告)日：2017-02-28
申请号：US15031301
申请日：2014-10-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Yaofeng Cheng , Weiqi Chen , Brad D. Maxwell , Bach D. Tran , Jun Li
IPC: A61K31/44 , C07D401/00 , C07D471/04 , C07B59/00 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , C07B59/002 , C07B2200/05
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
Abstract translation: 提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。 这些新的式I化合物或其立体异构体或其药学上可接受的盐，其中R *是同位素标记的羟丙基部分。
-
Patent Agency Ranking
公开(公告)号：US20250002497A1
公开(公告)日：2025-01-02
申请号：US18826736
申请日：2024-09-06
Applicant: Bristol-Myers Squibb Company , Université De Montréal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/04 , C07B59/00 , C07D513/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R1, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US12084452B2
公开(公告)日：2024-09-10
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/04 , C07B59/00 , C07D513/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US20180305376A1
公开(公告)日：2018-10-25
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/5377 , A61K31/435 , C07D487/04 , A61K31/541 , A61K31/553 , A61K31/433 , A61K31/496 , A61K31/497 , A61K31/454 , A61K45/06 , A61K31/4439 , A61K31/5025 , C07B59/00 , A61K31/55 , A61K51/04 , A61K31/5386 , C07D519/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
9.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑并吡啶衍生物公开(公告)号：US20150094297A1
公开(公告)日：2015-04-02
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rèmillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/541 , A61K31/5377 , A61K31/5025 , C07D487/04 , A61K31/497 , A61K31/454 , A61K31/4439 , A61K31/433 , A61K31/553 , A61K31/496
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式I的噻唑化合物，其中W，Y，R0，R2，R4，R5，R6，R7，X1，X2，X3和X4如本文所定义，或立体异构体，互变异构体，药学上可接受的盐， 或其溶剂合物形式，其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
10.发明公开公开(公告)号：US20230242535A1
公开(公告)日：2023-08-03
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/454 , A61K31/5386 , A61K31/496 , A61K45/06 , C07B59/00 , A61K31/4439 , A61K31/5025 , A61K31/497 , A61K31/435 , A61K51/04 , A61K31/55 , C07D519/00 , A61K31/553 , A61K31/5377 , A61K31/433 , C07D513/04 , A61K31/541
CPC classification number: C07D487/04 , A61K31/55 , A61K31/433 , A61K31/435 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/4439 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.043 seconds)
